First Trust Advisors LP Sells 58,194 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

First Trust Advisors LP lowered its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 66.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,818 shares of the company’s stock after selling 58,194 shares during the quarter. First Trust Advisors LP’s holdings in Teva Pharmaceutical Industries were worth $657,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the company. Forum Financial Management LP boosted its stake in Teva Pharmaceutical Industries by 74.7% in the 4th quarter. Forum Financial Management LP now owns 18,118 shares of the company’s stock worth $399,000 after purchasing an additional 7,748 shares during the period. CANADA LIFE ASSURANCE Co grew its holdings in Teva Pharmaceutical Industries by 22.1% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 697,977 shares of the company’s stock valued at $15,371,000 after purchasing an additional 126,425 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Teva Pharmaceutical Industries by 87.8% during the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company’s stock worth $113,625,000 after acquiring an additional 2,410,420 shares during the last quarter. NewEdge Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries by 12.6% during the fourth quarter. NewEdge Advisors LLC now owns 35,482 shares of the company’s stock valued at $782,000 after purchasing an additional 3,983 shares during the period. Finally, Gabelli Funds LLC grew its stake in Teva Pharmaceutical Industries by 99.2% in the 4th quarter. Gabelli Funds LLC now owns 367,500 shares of the company’s stock worth $8,100,000 after acquiring an additional 183,000 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TEVA shares. Barclays decreased their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Bank of America increased their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Finally, Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.71.

Teva Pharmaceutical Industries Trading Up 3.0 %

Shares of Teva Pharmaceutical Industries stock opened at $18.13 on Friday. The firm’s 50-day moving average price is $15.16 and its 200 day moving average price is $17.47. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The firm has a market capitalization of $20.56 billion, a PE ratio of -12.50, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. During the same period in the prior year, the business earned $0.48 earnings per share. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. On average, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.